Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CETP | P11597 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24953211 | 1.00 | MAPT (0.47) | MAPTKMT2ACETPMEN1IDO1 | |
| SCHEMBL23515206 | 0.87 | HTR1B (0.46) | MAPTKMT2ACETPMEN1SMN1; SMN2 | |
| SCHEMBL30186245 | 0.87 | HTR1B (0.46) | MAPTKMT2ACETPMEN1SMN1; SMN2 | |
| SCHEMBL19766698 | 0.86 | MAPT (0.62) | MAPTKMT2ACETPMEN1SMN1; SMN2 | |
| SCHEMBL30186238 | 0.85 | HTR1B (0.55) | MAPTKMT2ACETPMEN1SMN1; SMN2 | |
| SCHEMBL23515212 | 0.82 | CETP (0.52) | MAPTKMT2ACETPMEN1POLB | |
| SCHEMBL29209220 | 0.81 | SLC2A1 (0.46) | MAPTKMT2ACETPMEN1SMN1; SMN2 | |
| SCHEMBL28765665 | 0.81 | NCEH1 (0.57) | IDO1 | |
| SCHEMBL28765607 | 0.80 | IDO1 (0.50) | MAPTKMT2AMEN1IDO1 | |
| SCHEMBL23515386 | 0.80 | CYP1A2 (0.71) | MAPTKMT2ACETPMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187681-B2 | Ion channel antagonists/blockers and uses thereof | SHANGHAI EAST HOSPITAL (CN) | 2025-01-07 | — | — | US | disclosed |
| US-20230015875-A1 | Ion Channel Antagonists/Blockers and Uses Thereof | SHANGHAI EAST HOSPITAL (CN) | 2023-01-19 | — | — | US | disclosed |
| CN-114401935-A | Ion channel antagonists/blockers and uses thereof | 上海市东方医院（同济大学附属东方医院） | 2022-04-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230015875-A1 | Ion Channel Antagonists/Blockers and Uses Thereof | CACNA1F, CACNA1S, CACNA1D | MAPT 2678/4885KMT2A 3777/4885CETP 1967/4885 |
| US-12187681-B2 | Ion channel antagonists/blockers and uses thereof | CACNA1F, CACNA1S, CACNA1D | MAPT 2678/4885KMT2A 3777/4885CETP 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.